Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.

drug protocol number

BA2011/03/04

drug sponsor

Onxeo

drug study

Doxorubicin

drug trial site

King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah)

drug status

Completed

drug phase